ABBV vs GILD
By Alex · Tickerpine
AbbVie Inc. vs Gilead Sciences, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | GILD |
|---|---|---|
| Price | $295.03 | $168.08 |
| Market cap | $521.50B | $208.48B |
| P/E ratio | 50.7 | — |
| ROE | — | -22.45% |
| Profit margin | 15.67% | -12.46% |
| Revenue growth | 10.30% | 6.80% |
| Dividend yield | 2.35% | 1.95% |
| Beta | 0.19 | 0.37 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs GILD in plain English
- ABBV is the bigger company — about 2.5× the market cap of GILD.
- ABBV is growing revenue faster (10% vs 7%).
- ABBV has the higher dividend yield (2.35% vs 1.95%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
GILD return calculator
See what $1,000 in Gilead Sciences, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.